Office: 918 Salk Hall
Sandra L. Kane-Gill, PharmD, MS, FCCM, FCCP, is Associate Professor of Pharmacy and Therapeutics at the University of Pittsburgh School of Pharmacy in Pittsburgh, Pennsylvania. She has secondary appointments in the School of Medicine in the Clinical Translational Science Institute, Deparment of Critical Care Medicine and the Department of Biomedical Informatics. She also serves as Associate Professor for the Center for Critical Care Nephrology and Center for Pharmaceutical Policy and Prescribing. In addition to her academic appointments, Dr. Kane-Gill is Critical Care Medication Safety Pharmacist at the University of Pittsburgh Medical Center in the Department of Pharmacy.
Dr. Kane-Gill received her Bachelor of Science degree in pharmacy from Wayne State University in Detroit, Michigan. She completed a pharmacy practice residency accredited by the American Society of Health-System Pharmacists at West Virginia University Hospital in Morgantown, West Virginia, and earned a Doctorate of Pharmacy degree from the University of Toledo in Toledo, Ohio. Dr. Kane-Gill then pursued her Master of Science degree in Pharmacy Administration with emphasis on Pharmacoeconomics and Health Outcomes at The Ohio State University in Columbus, Ohio and she completed a critical care fellowship at The Ohio State University.
Dr. Kane-Gill’s interests focus on health service research, including the assessment of economic, clinical, and quality outcomes for critically ill patients. Her goal is to identify effective approaches for the detection, prevention, and management of medication errors and adverse drug events as to improve quality of care and patient safety. Dr. Kane-Gill has served as Principal Investigator and Co-Investigator on several funded research grants in this area of study. Most recently, she received an AHRQ R18 grant entitled "Transforming the Medication Regimen Review Process of High-Risk Drugs Using a Patient-Centered Telemedicine-Based Approach to Prevent Adverse Drug Events in the Nursing Home" (R18HS02420-01). Her work has been presented at several professional meetings, and she has published more than 100 articles and book chapters related to critical care and patient safety. Her endeavors include editing published books on the use of high-risk intravenous medications in special patient populations and drug induced complications in critically ill patients. She is on the editorial board for Critical Care Medicine, Annals of Pharmacotherapy and Hospital Pharmacy (critical care column). She is currently the editor of Critical Connections a newsmagazine that is developed and distributed by the Society of Critical Care Medicine.
Dr. Kane-Gill is an active member of the American College of Clinical Pharmacy (ACCP), and Society of Critical Care Medicine (SCCM). She holds the elected position of member-at-large seat for the Society of Critical Care Medicine (SCCM) Council, which is the decision-making body regarding the governance of SCCM. At the 2011 Annual Meeting of ACCP, Dr. Kane-Gill received the Critical Care Practice and Research Network (PRN) Research Award and in 2013 received the Critical Care Achievement Award. At the 2012 SCCM meeting she was recognized for her contributions in medication safety error prevention with the Clinical Pharmacy and Pharmacology Section Technology Patient Safety Award. She is a fellow in the American College of Critical Care Medicine and the American College of Clinical Pharmacy.
Dr. Kane-Gill’s interests focus on health service research including the assessment of economic, clinical and quality outcomes. Her goal is to identify effective approaches for the detection, prevention and management of medication errors and adverse drug events to improve quality of care and promote patient safety. She has led several pharmacopidemiology evaluations that improved patient safety surveillance systems, prevented medication errors and adverse drug events, used patient reported outcomes to improve quality of care, used information technology to improve services and developed models of cost for acute illness. To ensure the optimal quality of care for patients she has also completed several comparative effectiveness trials that analyze the safe use of high-risk drugs such as anticoagulants. Several of the pharmacoepidemiology studies she has completed used large administrative databases to accomplish the study endpoints with the largest including 20 million patients. She has served as Principal Investigator and Co-Investigator on several funded research grants in this area of study. Her work has been presented at several national and international professional meetings.